Smruthi Organics Ltd
NSE: BSE: 540686
₹111.25
(-1.16%)
Fri, 27 Feb 2026, 06:13 pm
Market Cap1.29B
PE Ratio27.75
Dividend1.33
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1995
- The company decided to expand its product range by introducing Ciprofloxacin and Ranitidine HCl.
- The company entered the capital market with a public issue of 18,88,550 lakh equity shares.
2005
- The Company's Block No C and D received 100% EOU status permission from the Development Commissioner, Seepz, Mumbai and started export activities.
2006
- The Company commenced commercial operation of its new 'E' Block production plant as an Export Oriented Unit.
- The Board of Directors recommended a dividend of 25% for the financial year.
2007
- The Company received the Current Good Manufacturing Practices - World Health Organization certificate from German Health Authorities for Active Pharmaceutical Ingredients.
2009
- Amlodipine Besilate (API) was granted Certificate of Suitability by the European Directorate for the Quality of Medicines and Healthcare.
2011
- Smruthi Orga - Manufacturing site U-II received USFDA approvals.
- The company recommended a dividend of 25% on Equity Shares.
2012
- The Board of Directors recommended a dividend of 30% on Equity Shares of Rs. 10/- each for the year.
2021
- The Company issued Bonus Shares in the Ratio of 2:1.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800